Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of 100 mg Multiple Doses of GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Next Previous
Trial Profile

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of 100 mg Multiple Doses of GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Galapagos NV

Most Recent Events

  • 08 Aug 2018 Results published in the British Journal of Clinical Pharmacology.
  • 08 Nov 2015 Results will be presented at the American College of Rheumatology (ACR) Annual Meeting 2015, according to a Galapagos NV media release.
  • 21 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top